|Day Low/High||28.00 / 29.26|
|52 Wk Low/High||6.75 / 39.50|
In recent trading, shares of Evolus Inc have crossed above the average analyst 12-month target price of $22.50, changing hands for $23.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Here's what you need to know now for Thursday, May 17.
The chief commercial officer's appearance at a Bank of America healthcare conference came a day after Allergan competitor Evolus said it had received a complete response letter regarding its application for Botox rival DWP-450.
Holzer & Holzer, LLC is investigating whether Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS) complied with the federal securities laws.
Results presented today at 2018 Aesthetic and Anti-Aging Medicine World Congress (AMWC)
This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
Trial Results to be Presented at American Academy of Dermatology Meeting
The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.